Welcome to our dedicated page for Zentalis Pharmaceuticals SEC filings (Ticker: ZNTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as it advances azenosertib, an investigational WEE1 inhibitor, through clinical development. As a clinical-stage biopharmaceutical issuer, Zentalis files Forms 10-K and 10-Q for annual and quarterly reporting, along with Form 8-K current reports detailing material events related to its oncology programs, financial position and corporate governance.
Recent Form 8-K filings describe financial results and operational progress, including updates on the DENALI Phase 2 trial in Cyclin E1-positive platinum-resistant ovarian cancer (PROC), cash, cash equivalents and marketable securities levels, and the company’s view of its operational runway. Other 8-Ks report leadership and board changes, such as transitions in the Chief Legal Officer and Corporate Secretary role, a director resignation with a corresponding reduction in board size, and a stock repurchase from a major shareholder. These filings often incorporate press releases by reference, providing additional detail on clinical and corporate developments.
Investors can also review disclosures related to stockholder meetings and voting results, such as the annual meeting outcomes for director elections, auditor ratification and advisory votes on executive compensation. Equity compensation arrangements, including inducement stock option grants under the company’s employment inducement incentive award plan, are reported in connection with Nasdaq Listing Rule 5635(c)(4).
On Stock Titan, ZNTL filings are supplemented with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand how Zentalis’ SEC reports address azenosertib’s clinical status, biomarker-driven strategy, cash resources and governance matters. Users can track new filings in real time as they are posted to EDGAR, and use these insights alongside news and market data to build a more complete picture of Zentalis’ risk profile and development trajectory.
Zentalis Pharmaceuticals furnished an update on its WEE1 inhibitor azenosertib, highlighting new preclinical and real‑world data presented at the AACR 2026 meeting in San Diego. In triple‑negative breast cancer models, azenosertib showed 42–99% tumor growth inhibition as monotherapy and drove stronger responses when combined with antibody‑drug conjugates or paclitaxel, including complete responses in 7 of 8 mice in an ADC‑resistant model.
Real‑world analyses in high‑grade serous ovarian cancer showed Cyclin E1‑positive patients had shorter time to next treatment after first‑line therapy, at 13.2 and 14.9 months in two groups versus 19.5 months for Cyclin E1‑negative patients, underscoring a poor‑prognosis population Zentalis is targeting with late‑stage azenosertib studies.
Zentalis Pharmaceuticals is advancing its WEE1 inhibitor azenosertib in platinum-resistant ovarian cancer by selecting 400mg once daily on a 5-days-on, 2-days-off schedule as the pivotal monotherapy dose for Cyclin E1-positive patients. This choice is based on a prespecified interim analysis from the DENALI Phase 2 Part 2a trial, which showed a clearly differentiated response rate versus 300mg with broadly comparable safety.
The 400mg QD 5:2 dose will be used across the registration-intended DENALI Phase 2 study and the confirmatory ASPENOVA Phase 3 trial, expected to initiate in Q2 2026 and enroll about 420 patients against investigator’s-choice chemotherapy. Zentalis plans a DENALI Part 2 topline readout by year-end 2026 and continues to target an accelerated approval pathway. In integrated datasets, azenosertib at 400mg QD 5:2 in Cyclin E1-positive PROC has shown objective response rates above 30% with median duration of response around five to six months, alongside a manageable safety profile. The company estimates roughly 21,500 Cyclin E1-positive PROC patients, about half of the PROC population, and reports $245 cash, cash equivalents and marketable securities as of December 31, 2025, which it believes can fund operations into late 2027.
Zentalis Pharmaceuticals is a clinical-stage biopharma company focused on developing azenosertib (ZN‑c3), an oral WEE1 inhibitor, primarily for Cyclin E1‑positive platinum‑resistant ovarian cancer (PROC). The company has no approved products and relies on external manufacturers and collaborators.
Azenosertib has shown single‑agent anti-tumor activity with objective response rates around one‑third in Cyclin E1‑positive PROC across multiple studies, using an intermittent 400 mg once‑daily 5:2 schedule. Zentalis believes the Phase 2 DENALI Part 2 study, if successful, could support accelerated U.S. approval, with the Phase 3 ASPENOVA trial planned as a confirmatory study.
The company highlights a sizable biomarker‑defined market opportunity in PROC and potential expansion into earlier ovarian cancer lines and other solid tumors. Key risks include continued losses, substantial capital needs, dependence on a single lead asset, complex regulatory pathways, competition from other WEE1 and oncology approaches, and reliance on third‑party manufacturers and CROs.
Zentalis Pharmaceuticals reported full-year 2025 results showing continued investment in its lead WEE1 inhibitor azenosertib while narrowing losses. The company ended 2025 with $245.9 million in cash, cash equivalents and marketable securities and expects this to fund operations into late 2027, beyond the planned DENALI Part 2 topline readout.
Revenue from licensing and intellectual property dropped to $0 in 2025 from $67.4 million in 2024, while net loss attributable to Zentalis improved to $137.1 million from $165.8 million. Research and development expenses declined to $107.3 million and general and administrative expenses to $37.7 million, reflecting sizable cost reductions and a restructuring charge of $7.8 million.
Clinically, Zentalis completed enrollment in DENALI Part 2a, aligned with the FDA on the Phase 3 ASPENOVA trial design, and is advancing the MUIR study of azenosertib plus bevacizumab in ovarian cancer. Key 2026 milestones include DENALI dose confirmation and Phase 3 ASPENOVA initiation in the first half of 2026, and DENALI Part 2 topline data by year-end, which could potentially support accelerated approval subject to FDA feedback.
Zentalis Pharmaceuticals, Inc. Schedule 13G reports that Squadron Master Fund LP (and related advisor and partners) beneficially hold 3,676,900 shares of common stock, representing 5.1% of the class.
The filing states this percentage is based on 72,250,779 shares outstanding as of November 1, 2025. The reporting persons disclose shared voting and shared dispositive power over the 3,676,900 shares and include a Rule 13d-4 disclaimer of beneficial ownership.
Zentalis Pharmaceuticals chief medical officer Ingmar Bruns reported automatic sales of company common stock to cover tax withholding on vested restricted stock units. On February 6, 2026, 2,962 shares were sold at $2.4297 per share, followed by 335 shares at $2.3929 per share on February 9, 2026. After these transactions, Bruns beneficially owned 33,332 shares of Zentalis common stock directly.
Zentalis Pharmaceuticals officer Vincent Vultaggio, who serves as PAO and PFO, reported several sales of company common stock. On February 6, 2026, he sold 29,951 shares at $2.4297 per share. On February 9, 2026, he sold 3,379 shares at $2.3929 per share, and on February 10, 2026, he sold 6,894 shares at $2.4223 per share. A footnote explains the first sale was made automatically by the company to cover tax withholding on vesting restricted stock units, while the later sale was executed under a pre-established Rule 10b5-1 trading plan. After these transactions, Vultaggio directly held 146,506 shares of Zentalis common stock.
Zentalis Pharmaceuticals, Inc. reported an insider transaction by its CEO & President and director, Julia Marie Eastland. On February 6, 2026, 7,866 shares of common stock were sold at $2.4297 per share, leaving 80,022 shares owned directly. On February 9, 2026, a further 889 shares were sold at $2.3929 per share, leaving 79,133 shares owned directly.
According to the footnote, these sales were made automatically by the issuer to cover tax withholding obligations arising from the vesting and settlement of restricted stock units previously granted to Eastland, rather than discretionary open-market sales.
Zentalis Pharmaceuticals officer Vincent Vultaggio reported two sales of common stock. On February 2, 2026, he sold 2,540 shares at $2.55 per share, an automatic sale by the company to cover tax withholding on vested restricted stock units.
On February 3, 2026, he sold 556 shares at $2.515 per share under a pre-arranged Rule 10b5-1 trading plan. After these transactions, he beneficially owned 186,730 shares of Zentalis common stock in direct form.
Zentalis Pharmaceuticals, Inc. reported that officer Vincent Vultaggio received a stock option grant for 100,000 shares on January 8, 2026. The options have an exercise price of $2.84 per share and expire on January 7, 2036. Following this grant, he beneficially owns 100,000 stock options directly.
According to the footnote, the options vest over four years in substantially equal monthly installments, and vesting depends on his continued service with the company. This structure ties the long-term value of the award to his ongoing tenure and the company’s future performance.